A once-weekly GLP-1 medication, may help in weight management with potential heart protection.^1*

* In addition to reduced-calorie diet and increased physical activity

Learn About Wegovy^®

Talk to Your Doctor – Begin Your Scientific Weight Management Journey

Contains the active ingredient semaglutideWegovy^®contains the active ingredient semaglutide, a new generation GLP-1 receptor agonist.¹It is a prescription medication may be suitable for individuals concerned about weight management.¹Once-weekly injectionWegovy^®is a once-weekly injection that may help reduce appetite, promote weight loss, and support weight management.¹Major Health Authorities approvedWegovy^®is approved for use by Hong Kong Department of Health, FDA and
EMA.^2-4
*FDA: Food and Drug Administration (the U.S.)
EMA: European Medicines Agency.Ensure that the product in your hands is genuine.
We offer three ways to help you quickly and immediately verify and distinguish authenticity.Authentication Info Wegovy^®is a prescription medication. If you are concerned about weight management, please consult your doctor for further information.For those concerned on weight managementTaking Wegovy^®

References 1. Wegovy^®Hong Kong Prescribing Information. 2. FDA News Release. Available at: https://bit.ly/47zoWWQ. Accessed: Aug 2025. 3. European Medicines Agency. Wegovy (semaglutide). An overview of Wegovy and why it is authorised in the EU. Available at: https://www.ema.europa.eu/en/documents/overview/wegovy-epar-medicine-overview_en.pdf. Accessed: Aug 2025. 4. Department of Health. https://www.drugoffice.gov.hk/eps/drug/productDetail2/en/consumer/145967 (Assessed 09-Oct 2025) 5. Bettadapura, et al.2025;49:418-426. Wegovy^®is a prescription medicine. For details, please consult your medical doctor.
This material is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. For any inquiries, please consult a qualified healthcare professional. HK25SEMO00046 Nov/2025